Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Novo Nordisk stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 13, 2026

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

Subtopics

Clinical trials2Drug Policy, Pricing & Approval2Adolescent health1Childhood obesity1Drug safety1Eli Lilly1Fast track designation1FDA drug approval1GLP-1 drugs1Hematology1Obesity treatment1Orphan drug designation1Pharmaceutical Industry1Rare diseases1Weight loss drugs1Zepbound1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories